Board of Jubilant Pharma approves acquisition of speciality pharma business in US
Jubilant Life Sciences announced that the Board of Jubilant Pharma (JPL), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
